HMGN1 and neoplasm: In mice, studies of colon and Lewis Lung Carcinoma (LLC) models demonstrated that a treatment combining anti-PD-L1 and a stimulatory high-mobility group nucleosome binding domain 1 (HMGN1) peptide called minP1 led to tumor regression, immunological memory, and increased survival rates by stimulating mregDCs (69).